skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101 (Code C111688)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101

Definition: A liposomal nanoparticle-based therapeutic vaccine composed of the cationic lipid R-DOTAP (R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride) encapsulating six human papillomavirus 16 (HPV-16) E6 and E7 peptides, with potential immunostimulating activity. Upon subcutaneous administration of the liposomal HPV-16 E6 and E7 multipeptide vaccine, the nanoparticles are taken up by antigen presenting cells (APCs), specifically dendritic cells (DCs), which may stimulate the immune system to induce a cytotoxic T-lymphocyte response (CTL) against HPV-16 E6 and E7-expressing tumor cells. HPV-16 E6 and E7 are oncoproteins that play a key role in the tumorigenesis of a variety of cancers.

Display Name: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101

Label: Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101

NCI Thesaurus Code: C111688 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: CL454078  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101
mmunoMAPK-RDOTAP /HPV-16 E6/E7 Peptide Antigen Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 752827
PDQ Open Trial Search ID 752827 (check for NCI PDQ open clinical trial info)

Other Properties:
     Name Value (qualifiers indented underneath)
code C111688
Contributing_Source CTRP
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom